An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol
PLOS ONE · 08.01.2025 · 20 (1) · e0311900
DOI: 10.1371/journal.pone.0311900 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PLOS ONE, online erschienen am 08.01.2025. Verfasst von Emmanuel Peprah und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global and Environmental Health, Implementing Sustainable Evidenced-based interventions through Engagement (ISEE Lab), NYU School of Gl…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hydroxyurea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Background
Despite the proven efficacy of evidence-based healthcare interventions in reducing adverse outcomes and mortality associated with Sickle Cell Disease (SCD), a vast majority of affected individuals in Africa remain deprived of such care. Hydroxyurea (HU) utilization among SCD patients in Sub-Saharan Africa (SSA) stands at less than 1%, while in Nigeria, approximately 13% of patients benefit from HU therapy. To enhance HU utilization, targeted implementation strategies addressing provider-level barriers are imperative. Existing evidence underscores the significance of addressing barriers such as inadequate healthcare worker training to improve HU adoption. The ACCELERATE study aims to evaluate the adoption of HU among providers through the Screen, Initiate, and Maintain (SIM) intervention, facilitated by healthcare worker training, clinical reminders, and task-sharing strategies, thereby enhancing patient-level SCD management in Nigeria.
Methods
This study will implement the SIM intervention, encompassing patient screening, initiation of HU treatment, and maintenance of dosage, which will be implemented via the TAsk-Strengthening Strategy for Hemoglobinopathies (TASSH TCP), derived from our team’s TAsk-Strengthening Strategy for Hypertension control (TASSH) trials. Employing a sequential exploratory mixed-methods approach within the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework, this study will assess SIM adoption by providers in Nigeria. The primary outcome is the rate of SIM adoption at clinical sites at 12 months, with secondary outcomes including sustainability/maintenance of SIM intervention and implementation fidelity.
Discussion
This study’s findings will offer crucial insights into effective SCD management strategies, leveraging existing SCD clinical networks and resources in Nigeria to enhance HU adoption among providers in a scalable and sustainable manner. Additionally, the study will inform best practices for implementing HU therapy in resource-constrained settings, benefiting healthcare providers, policymakers, and stakeholders invested in improving SCD care delivery.
Trial registration
NCT06318143 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Global and Environmental Health, Implementing Sustainable Evidenced-based interventions through Engagement (ISEE Lab), NYU School of Global Public Health, New York, NY, United States of America.
- Institute for Excellence in Health Equity, NYU Langone Medical Center, New York, NY, United States of America.
- Department of Biostatistics, NYU Langone Medical Center, New York, NY, United States of America.
- Cardiovascular Research Unit, Department of Internal Medicine, Faculty of Clinical Sciences, University of Abuja, Gwagwalada, Abuja, Nigeria.
- Centre of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria.
- Department of Chemical Pathology, Faculty of Basic Clinical Sciences, College of Health Sciences, University of Abuja, Abuja, Nigeria.
ORCID-Profile: Emmanuel Peprah, Hezekiah Isa, Grace Shedul
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Peprah, E., Gyamfi, J., Patena, J., Kayalioglu, H., Hameed, T., Ogedegbe, G., Do, H., Ojji, D., Adenikinju, D., Ajaye Oba, T., Nwegbu, M., Isa, H., Shedul, G., Sopekan, A. Y., & Nnodu, O. E. (2025). An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol. PLOS ONE, 20(1), e0311900. https://doi.org/10.1371/journal.pone.0311900
Vancouver
Peprah E, Gyamfi J, Patena J, Kayalioglu H, Hameed T, Ogedegbe G, et al. An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol. PLOS ONE. 2025;20(1):e0311900. doi:10.1371/journal.pone.0311900
BibTeX
@article{Peprah2025,
author = {Peprah, Emmanuel and Gyamfi, Joyce and Patena, John and Kayalioglu, Hazal and Hameed, Tania and Ogedegbe, Gbenga and Do, Hyungrok and Ojji, Dike and Adenikinju, Deborah and Ajaye Oba, Tayo and Nwegbu, Maxwell and Isa, Hezekiah and Shedul, Grace and Sopekan, Alayo Y and Nnodu, Obiageli E},
title = {An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol},
journal = {PLOS ONE},
year = {2025},
volume = {20},
number = {1},
pages = {e0311900},
doi = {10.1371/journal.pone.0311900}
}
EUVIMED